If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer.
Top news of the day across the health care landscape.
The FDA announced approval of Wixela Inhub on January 30, 2019.
Biologic therapy used to treat severe psoriasis found to improve coronary artery plaque burden.
The new approval allows for daratumumab (Darzalex) to be administered as a split infusion over 2 consecutive days.
Zogenix is seeking approval for its low-dose fenfluramine therapy, ZX008 (Fintepla), for the treatment of seizures associated with Dravet syndrome.
Top news of the day across the health care landscape.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.